Hikal Limited

Hikal Limited's fiscal year 2026 results reveal a complex picture for investors, marked by both recovery and challenges. While the company reported a sequential improvement in its pharmaceutical business and a robust 45% quarter-over-quarter increase in crop protection revenue, a net loss of ₹487 million for the year reflects the impact of exceptional items, including asset impairments and provisions for new labor codes. Furthermore, the disclosure of revenue recognition irregularities in Q2 FY26, though deemed to have no financial impact, introduces governance concerns. Despite these headwinds, Hikal maintains a commitment to shareholder returns, declaring a 30% total dividend for the year and progressing with strategic investments in high-potency APIs and diversification into new chemical segments, suggesting a focus on long-term growth despite near-term uncertainties.